Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Clinical results of Mitraclip in degenerative mitral valve regurgitation”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Carlos Fava. Repairing the mitral valve with Mitraclip has become an alternative for high risk or inoperable symptomatic patients, but its long term evolution has only been tested by the EVEREST II, which had not taken into account 5 year mortality outcomes. Therefore, to better study its evolution, we need to carry out different randomized studies...
Courtesy of Dr. Carlos Fava The EVEREST II trial showed the MitraClip had similar mortality rate to that of surgery but, even though residual mitral valve regurgitation (MR) is associated to a strong negative impact, little is known about post MitraClip increased transvalvular gradient and its implication. 268 patients undergoing MC implantation were analyzed....
Current surgical and medical treatment options for severe tricuspid regurgitation are extremely limited. However, this historically forgotten valve seems to have the option of transcatheter repair, nowadays. This observational study assessed the safety and feasibility of the MitraClip system for patients with severe chronic tricuspid regurgitation. All patients presented severe tricuspid regurgitation and...
Courtesy of Dr. Carlos Fava. Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established. 760 patients were analyzed; 315 (52.4%) presented...
Location: Aloysio de Castro State Cardiology Institute – (IECAC). Operators: Márcio Montenegro, Edgard Quintella, Estêvão Martins. Chairpersons: Fabio Sândoli de Brito Jr., Dimytri Alexandre de Alvim Siqueira. Panelists: Márcio José Montenegro da Costa, Ricardo Mourilhe Rocha, Rogério Eduardo Gomes Sarmento Leite, José Armando Mangione, Salvador André Bavaresco Cristovão. Broadcasted on June 8, 2016 by TBR...
Courtesy of Dr. Carlos Fava. Patients with severe mitral regurgitation unfit for surgery due to high surgical risk are likely to develop chronic kidney disease (CKD). There is limited information available on patients with CKD receiving MitraClip. This study analyzed patients receiving MitraClip and presenting chronic kidney disease. CKD was defined as a...
Original Title: Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. 5 – Years Results of EVEREST II. Reference: Ted Feldman et al. J Am Coll Cardiol 2015;66:2844-54 Courtesy of Dr. Carlos Fava The MitraClip at 12 months in the EVEREST II trial showed similar outcomes to that of surgery, with improved ventricular remodeling and...
Original title: Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. Reference: Swaans MJ et al. J Am CollCardiolIntv. 2014;7:875-881. In high-surgical-risk patients with symptomatic severe mitral valve regurgitation, MitraClip for transcatheter mitral valve repair and surgery showed similar survival rates in addition to superiority when compared to standard medical treatment. This...
Original title: Acute outcomes after MitraClip® therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. Reference: Wolfgang Schillinger et al. EuroIntervention 2013; 8-online publish-ahead-of-print April 2013. Recently, percutaneous repair of the mitral valve with MitraClip®, (Abbott Vascular, Santa Clara, CA, USA), has emerged as an option for patients with severe mitral regurgitation,...